Release Details

A scientist inside the laboratory testing specimens

Biogen to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at investors.biogen.com.  An archived version of the webcast will be available following the presentation.

About Biogen
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and is providing the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing the industry’s most diversified pipeline in neuroscience that will transform the standard of care for patients in several areas of high unmet need.

In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter, LinkedIn, Facebook, YouTube.


Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442
 

Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs